<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-P38</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-P38</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Optimising structural imaging of neuroendocrine tumours in the molecular imaging age</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Parameswaran</surname><given-names>Bimal Kumar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drbimalkumar@yahoo.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Moodie</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Hofman</surname><given-names>Michael S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Peter MacCallum Cancer Centre, Melbourne, Australia</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>P38</fpage><lpage>P38</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Parameswaran et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Parameswaran et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/P38"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title>Aim</title><p>To provide an educational update on structural imaging appearances of neuroendocrine tumours (NET), in the age of molecular imaging.</p><p>PET/CT with Ga-68 DOTA-TATE and F-18 fluorodeoxyglucose (FDG) is providing new understanding of neuroendocrine tumours including patterns and heterogeneity of disease. This is also providing new insights of structural imaging findings including CT and MRI. It is also important to be aware of the limitations of PET/CT imaging, and we outline indications where structural imaging has a high impact for patient management. These changing paradigms are translating to revised imaging protocols in our institution that are enabling personalised medicine with appropriate selection of management for an individual patient. It is also allowing us to understand the structural imaging appearances of heterogeneity within the same tumour type. A range of new targeted therapies including peptide receptor radionuclide therapy (PRRT) are now available to treat patients with non-resectable metastatic NET. New patterns of response are emerging which are important to recognise, including cystic necrosis which may initially masquerade as progressive disease due to enlargement.</p><p>We have a large population of patients with neuroendocrine tumours at Peter MacCallum Cancer Institute, providing wide experience of this spectrum of imaging findings across various subtypes of NET. We present a pictorial review of our experience.</p></sec></body></article>
